Kite's Yescarta to receive European marketing authorisation

First treatment in 30 years to improve second-line treatment of DLBCL - News - PharmaTimes

Related Keywords

Christi Shaw ,John Gribben ,Cancer Research United Kingdom Barts Centre ,Gilead Company ,European Commission ,Chimeric Antigen Receptor ,Professor John Gribben ,Cancer Research United Kingdom Barts ,Kite ,Descarta ,Marketing ,